Antonio Heras‐Garvin

Innsbruck Medical University — Austria

Medicine · Health Sciences

14h-index588citations38works0.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Parkinson's Disease Mechanisms and Treatments(21), Alzheimer's disease research and treatments(9), Neuroinflammation and Neurodegeneration Mechanisms(9), Neurological diseases and metabolism(9), Nuclear Receptors and Signaling(8)

Publications38 total

Clinically advanced NLRP3 inhibitor modulates microglial transcriptome and alleviates α-synuclein-induced progression of parkinsonism
Figshare·2026Open Access
Clinically advanced NLRP3 inhibitor modulates microglial transcriptome and alleviates α-synuclein-induced progression of parkinsonism
Journal of Neuroinflammation·2026Open Access
Additional file 1 of Clinically advanced NLRP3 inhibitor modulates microglial transcriptome and alleviates α-synuclein-induced progression of parkinsonism
Figshare·2026Open Access
Additional file 1 of Clinically advanced NLRP3 inhibitor modulates microglial transcriptome and alleviates α-synuclein-induced progression of parkinsonism
Figshare·2026Open Access
Additional file 2 of Clinically advanced NLRP3 inhibitor modulates microglial transcriptome and alleviates α-synuclein-induced progression of parkinsonism
Figshare·2026Open Access
Additional file 2 of Clinically advanced NLRP3 inhibitor modulates microglial transcriptome and alleviates α-synuclein-induced progression of parkinsonism
Figshare·2026Open Access
Clinically advanced NLRP3 inhibitor modulates microglial transcriptome and alleviates α-synuclein-induced progression of parkinsonism
Figshare·2026Open Access
Multiparametric MRI and imaging transcriptomics reveal molecular and cellular correlates of neurodegeneration in experimental parkinsonism
2025Open Access
Pharmacologic NLRP3 Inhibition Modulates Parkinson’s Disease-Associated Microglial Transcriptomic Signatures and Mitigates α-Synuclein–Triggered Neurodegeneration
2025· 1 cited
Inactivation of the PHD3-FOXO3 axis blunts the type I interferon response in microglia and ameliorates Alzheimer’s disease progression
Science Advances·2025· 3 citedOpen Access
Transcriptional dysregulation in the cerebellum triggered by oligodendroglial α-synucleinopathy: insights from a transgenic mouse into the early disease mechanisms of MSA
Journal of Neural Transmission·2025· 3 citedOpen Access
The PHD3-FOXO3 axis modulates the interferon type I response in microglia aggravating Alzheimer’s disease progression
2024
Transcriptomic insights into multiple system atrophy from a PLP-α-synuclein transgenic mouse model
Brain Research·2024· 2 cited
Multiple System Atrophy
2022· 2 cited
The Concept of α-Synuclein Strains and How Different Conformations May Explain Distinct Neurodegenerative Disorders
Frontiers in Neurology·2021· 37 citedOpen Access
<scp>ATH434</scp> Reduces α‐Synuclein‐Related Neurodegeneration in a Murine Model of Multiple System Atrophy
Movement Disorders·2021· 23 citedOpen Access
Hypoxia compromises the mitochondrial metabolism of Alzheimer’s disease microglia via HIF1
Nature Aging·2021· 109 cited
ATH434 Preserves Dopaminergic Neurons, Reduces α-synuclein Oligomerization, and Improves Motor Function in a Transgenic Murine Multiple System Atrophy Model (1842)
Neurology·2021
Multiple System Atrophy
2021· 1 cited
Shared Genetics of Multiple System Atrophy and Inflammatory Bowel Disease
Movement Disorders·2020· 21 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Nadia Stefanova(17), Gregor K. Wenning(13), Magdalena Matić(8), Jasus Amo-Aparicio(8), Kelvin C. Luk(8), Michaela Tanja Haindl(8), Damaris B. Skouras(8), José López‐Barneo(7), Alberto Pascual(7), María Luque(7), Rosana March‐Díaz(6), Victoria Navarro(6), Marisa Vizuete(6), Javier Vitórica(6), Charles A. Dinarello(6), Nadia Stefanova(6), Nieves Lara-Ureña(5), Manuel A. Sánchez-García(5), Violetta Refolo(5), Carmen Romero‐Molina(4)